×
0 0 0 0 0 0 0 0.00955414012738844
Stockreport

New Publication Summarizes Phase 1 Studies of CK-2127107 Showing Tolerability and Amplification of Skeletal Muscle Response to Nerve Activation

CYTOKINETICS (CYTK)  More Company Research Source: GlobeNewswire
Last cytokinetics earnings: 11/1 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.cytokinetics.com/investor-overview
PDF Next Generation Fast Skeletal Muscle Activator Appears Promising Compared to Tirasemtiv in Studies of Healthy Volunteers SOUTH SAN FRANCISCO, Calif., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the publication of results from three double-blind, randomized, placebo-controlled Phase 1 clinical studies that evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of CK-2127107, an investigational next-generation fast skeletal muscle troponin activator (FSTA). The results showed that CK-2127107 increased the force generated by the tibialis anterior muscle versus placebo in response to nerve stimulation in a dose, plasma concentration, and frequency-dependent manner. Single doses of CK-2127107 were well-tolerated in healthy volunteers at doses up to 4000 mg. No serious adverse effects (SAEs) were reported and adverse effects (AEs) were all mild or moderate. Additionally, the results showed that CK-2127107 appeared more potent [Read more]

IMPACT SNAPSHOT EVENT TIME: CYTK
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
CYTK alerts
from News Quantified
Opt-in for
CYTK alerts

from News Quantified
Opt-in for
CYTK alerts

from News Quantified